Bristol-Myers Squibb (NYSE:BMY) is granting Dr. Reddy's Laboratories (NYSE:RDY) a volume-limited license to produce a generic version of its blockbuster multiple myeloma drug, Revlimid, beginning in 2022.

Previously, Bristol-Myers filed a patent-infringement lawsuit against Dr. Reddy's in an attempt to prevent the healthcare company from launching its generic version of Revlimid. In the second quarter, Revlimid produced $2.9 billion in revenue for Bristol-Myers.

A man speaking through a megaphone.

IMAGE SOURCE: GETTY IMAGES.

The newly inked agreement gives Dr. Reddy's the right to produce a limited amount of Revlimid beginning on an undisclosed date following March 2022, when an agreement with another generic drugmaker -- Natco -- kicks in. Restrictions limiting Dr. Reddy's production volume disappear on January 31, 2026.

The agreement allows Bristol-Myers to control how quickly Revlimid's revenue declines following its patent expiration, while also removing costs and uncertainty relating to Bristol-Myers litigation. Bristol-Myers acquired Revlimid when it bought Celgene in 2019 for approximately $74 billion.

There are over 32,000 patients diagnosed with multiple myeloma annually in the United States, making it the second most common blood cancer in the country.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.